Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
158 USD | +0.67% |
|
+27.90% | +63.81% |
26/06 | Monetary policy is getting even more confusing | ![]() |
26/06 | Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.81% | 14.93B | |
+16.13% | 122B | |
+19.65% | 113B | |
+19.27% | 26.49B | |
-23.84% | 19.4B | |
-18.24% | 16.24B | |
-45.95% | 15.15B | |
-19.28% | 15.4B | |
+1.94% | 13.52B | |
+116.04% | 10.79B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Barclays Adjusts Price Target on Sarepta Therapeutics to $226 From $185, Maintains Overweight Rating